Abstract
Purpose Immune checkpoint inhibitors (ICIs) are now indicated in more than one in three cancer patients. Acute kidney injury has emerged as an important complication of ICIs; however, there are no studies characterizing the long-term effects of ICIs on kidney function.
Methods Retrospective cohort study of consecutive adult cancer patients treated with ICIs between 2010–2018 at two major cancer centers. The primary aim was to determine the composite outcome of incident or progressive CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 or a ≥30% decline in eGFR sustained >90 days among patients surviving ≥1 year. The secondary objective was to determine the proportion of patients experiencing rapid eGFR decline defined as >3mL/min/1.73m2 per year decline.
Results A total of 5004 adult patients with cancer (mean [SD] age, 64 [13] years; 2699 [54%] male; 4529 [91%] White non-Hispanic) were included, and 2563 surviving ≥1 year were analyzed. During a median follow-up of 688 days (interquartile range, 496 to 1031), the overall event rate of the primary composite outcome was 17% and 20% at 3 and 5 years, respectively. Fine-Gray subdistribution multivariable hazard mode demonstrated that age and coronary artery disease were each independently associated with the primary outcome, adjusted HR (95% CI) 1.12 (1.06, 1.19) per 5 years and 1.27 (1.00-1.62), p < 0.001 and p=0.49, respectively.
Conclusion New onset CKD or 30% eGFR decline is common in patients receiving ICIs who survive ≥1 year. As ICIs are increasingly used in earlier stage cancers, the impact of long term kidney function decline among survivors is extremely important. Additional studies are needed to determine the risk factors and potential modifiers for eGFR decline among patients receiving ICIs.
Competing Interest Statement
Financial disclosures: LZ serves as a consultant for Merck. Dr. Neilan has been a consultant to and received fees from Parexel Imaging, Intrinsic Imaging, H3-Biomedicine, and AbbVie, outside of the current work. Dr. Neilan also reports consultant fees from Bristol Myers Squibb for a Scientific Advisory Board focused on myocarditis related to immune checkpoint inhibitors.
Clinical Trial
n/a
Funding Statement
Dr. Sise is supported by National Institutes of Health (NIH) K23 DK 117014 and the Claflin Distinguished Scholars Award. The NIH had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. TGN is suppored by (NIH) R01HL137562-, R01HL130539, and K24HL150238, and in part, through a kind gift from A. Curtis Greer and Pamela Kohlberg.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mass General Brigham IRB 857-282-1900 irb{at}partners.org IRB Protocol #: 2017P000501 Our IRB approved this study and waived the need for consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data can be made available upon request.
